At AbbVie, we have the expertise of a proven pharmaceutical leader and the focus and passion of an entrepreneur and innovator. The result is something rare in health care today – a global biopharmaceutical company that has the ability to discover and advance innovative therapies and meet the health needs of people and societies around the globe.
The Pharmaceuticals Division, our largest in terms of sales, is focused on the following areas in which we aim to make decisive contributions to medical progress: oncology, cardiology and hematology, gynecology, neurology, infectious diseases, men’s health, ophthalmology, and diagnostic imaging.
GENFIT is a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions to address high unmet patient needs in metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology.
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need.
MSD is a global healthcare leader working to address unmet health needs. We provide innovative medicines, vaccines, biologic therapies and animal health products to help improve health and well-being. We work with customers in 140 countries to deliver broad-based healthcare solutions. The company is known as Merck in the United States and Canada. Everywhere else, we are known as MSD.
We provide expertise and 'know how' in Europe to develop, commercialise and manufacture products that offer real value to payers, healthcare professionals and patients.
Promethera is currently focused on advancing cell-based medicines using its HepaStem platform into clinical trials in two disease areas, Acute-on Chronic Liver Failure (ACLF) and Nonalcoholic steatohepatitis (NASH). Both indications could benefit greatly from the combined immuno-modulatory and anti-fibrotic properties of HepaStem-derived cell lines.
Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases. Patients with these life-threatening diseases often have no effective treatment options, and they and their families suffer with little hope. Our goal is to deliver medical breakthroughs where none currently exist. We are driven because we know people's lives depend on our work.
At BTG we are focused on developing innovative products in specialist areas of medicine to better serve doctors and patients. Healthcare is constantly evolving – so BTG never stands still. Inspired by a deep understanding of our customers’ needs, we’re working to meaningfully improve the lives of patients and their healthcare experience.
Dr. Falk Pharma GmbH is an independent family firm based in Freiburg im Breisgau. In spite of its international presence, Dr. Falk Pharma and its 200 staff are still closely linked with the Freiburg region and the University of Freiburg. Our company specializes in the development and sales of medication for indications in hepatology and gastroenterology. These, mainly prescription drugs, are sold not only in Germany but also in a further 65 countries, often in co-operation with local partners but in some cases also via our own subsidiary companies
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases. Founded in 2002 in New York, New York, Intercept now has operations in the United States, Europe, Canada, and Australia.
Providing treatment options for patients with cancers of the liver. Sirtex is a global life-sciences company that develops and delivers effective oncology treatments using novel small particle technology.